AI Earnings Predictions for Haemonetics Corporation (HAE)

EX-99.1

2 ex991-fy27q1earningsrelease.htm

EX-99.1

Document

Exhibit 99.1

Investor ContactsMedia Contact

Olga Guyette, Vice President-Investor Relations & TreasuryJosh Gitelson, Sr. Director-Global Communications

(781) 356-9763(781) 356-9776

olga.guyette@haemonetics.com josh.gitelson@haemonetics.com

David Trenk, Sr. Manager-Investor Relations

(203) 733-4987

david.trenk@haemonetics.com

Haemonetics Reports First Quarter Fiscal 2027 Results;

Raises Total Company Fiscal 2027 Guidance

Boston, MA, August 6, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its first quarter of fiscal 2027, which ended June 27, 2026:

1st Quarter 2027

nRevenue, increase $339 million, 5.6%

n Organic(1) revenue increase 5.9%

nEarnings per diluted share$0.72

nAdjusted earnings per diluted share$1.14

nCash flow from operating activities$52 million

nFree cash flow$39 million

(1)    Excludes the impacts of currency fluctuation and the exit of certain liquid solution products.

Chris Simon, Haemonetics’ CEO, stated: “We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long-term growth and shareholder value.”

1

GAAP RESULTS

First quarter fiscal 2027 revenue was $339.4 million, up 5.6% compared with the first quarter of fiscal 2026. Business unit revenue and growth rates compared with the prior year period were as follows:

First Quarter Fiscal 2027 Reported

(Dollars in Millions)

Apheresis$191.35.3%

MedSurg$148.16.0%

Total net revenue$339.45.6%

Gross margin was 59.8% in the first quarter of fiscal 2027, which was relatively flat when compared with 59.8% in the first quarter of fiscal 2026. Operating expenses were $145.3 million, up $7.0 million, or 5.0%, compared with the first quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $57.5 million and a 16.9% operating margin in the first quarter of fiscal 2027, compared with operating income of $53.9 million and a 16.8% operating margin in the first quarter of fiscal 2026. The effective income tax rate was 30.6% in the first quarter of fiscal 2027, compared with 24.7% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls and valuation allowance impacts related to losses in certain recently acquired jurisdictions. First quarter fiscal 2027 net income and earnings per diluted share were $33.0 million and $0.72, respectively, compared with $34.0 million and $0.70, respectively, in the first quarter of fiscal 2026.

ADJUSTED RESULTS

First quarter organic revenue growth was 5.9% compared with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:

First Quarter Fiscal 2027

Organic

Apheresis6.0%

MedSurg5.9%

Total net revenue5.9%

First quarter fiscal 2027 adjusted gross margin was 60.4%, down 40 basis points compared with the prior year period. The primary drivers of the decrease in the adjusted gross margin percentage included upfront revenue recognition upon the execution of a long-term software agreement in the prior year, partially offset by the continued transformation of the product portfolio to higher-margin offerings and benefits from product innovation.

Adjusted operating expenses were $125.6 million, up $7.9 million, or 6.7%, compared with the first quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the first quarter of fiscal 2027 was $79.3 million, down $1.7 million, or 2.2%, compared with the first quarter of fiscal 2026. Adjusted operating margin was 23.4%, down 70 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the first quarter of fiscal 2027 was 25.7%, up 180 basis points when compared with 24.9% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls.

First quarter fiscal 2027 adjusted net income was $52.3 million, up $0.9 million, or 1.8%, and adjusted earnings per diluted share was $1.14, up 3.6%, each when compared with the same period of fiscal 2026.

2

BALANCE SHEET AND CASH FLOW

Cash on hand as of June 27, 2026 was $223.4 million, a decrease of $22.1 million since the end of fiscal 2026, primarily driven by cash outflows for the repayment of revolving credit facility borrowings and strategic investments, partially offset by cash flow pro

EX-99.1

2 ex991-q4mar2026earningsrel.htm

EX-99.1

Document

Exhibit 99.1

Investor ContactsMedia Contact

Olga Guyette, Vice President-Investor Relations & TreasuryJosh Gitelson, Sr. Director- Global Communications

(781) 356-9763(781) 356-9776

olga.guyette@haemonetics.comjosh.gitelson@haemonetics.com

David Trenk, Manager-Investor Relations

(203) 733-4987

david.trenk@haemonetics.com

Haemonetics Reports Fourth Quarter and Fiscal 2026 Results;

Provides Fiscal 2027 Guidance

Boston, MA, May 7, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2026, which ended March 28, 2026:

Fourth Quarter Fiscal 2026Fiscal 2026

n Revenue, increase/(decrease)

$346 million, 4.8%

$1.334 billion, (2.0)%

n Organic(1) revenue increase 4.5%1.1%

n Organic ex-CSL(2) revenue increase 8.6%9.5%

n (Loss) earnings per diluted share $(0.44)$2.05

n Adjusted earnings per diluted share $1.29$4.96

n Cash flow from operating activities $71 million$293 million

n Free cash flow $45 million$210 million

(1)    Excludes the impacts of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the exit of certain liquid solution products. The Company's acquisition of Vivasure Medical Limited ("Vivasure") in January 2026 had no impact on organic revenue growth rates and is not separately quantified.

(2)    In addition to the adjustments for organic revenue, further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

Chris Simon, Haemonetics’ CEO, stated: "Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma and Blood Management Technologies, and sequential improvement in Interventional Technologies. We successfully completed our four-year long-range plan, having built a more diversified, sustainable, and durable business and delivering impressive results against ambitious multi-year goals. With a strengthened competitive position and focus on disciplined execution, we have momentum for fiscal 2027 and beyond."

GAAP RESULTS

Fourth quarter fiscal 2026 revenue was $346.4 million, up 4.8% compared with the fourth quarter of fiscal 2025. Business unit revenue and growth rates compared with the prior year period were as follows:

Fourth Quarter Fiscal 2026 Reported

(Dollars in Millions)

Plasma$130.32.8%

Blood Center$56.40.7%

Hospital$159.68.0%

Total net revenue$346.44.8%

1

Gross margin was 57.2% in the fourth quarter of fiscal 2026, compared with 58.4% in the fourth quarter of fiscal 2025. The primary driver of the decrease in the gross margin percentage was a charge taken for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, partially offset by decreased restructuring costs related to portfolio rationalization initiatives and decreased amortization of fair value inventory step-up.

Operating expenses in the fourth quarter of fiscal 2026 were $221.2 million, an increase of $99.5 million, or 81.8%, when compared with the prior year period, driven by the impairment of intangible assets related to Attune Medical, partially offset by remeasurements of contingent consideration. Due to these charges, the Company had operating losses of $23.0 million and a (6.6)% operating margin in the fourth quarter of fiscal 2026, compared with operating income of $71.3 million and an operating margin of 21.6% in the fourth quarter of fiscal 2025. The income tax rates were 29.1% and 18.0% in the fourth quarters of fiscal 2026 and fiscal 2025, respectively. Additionally, due to the charges above, fourth quarter fiscal 2026 net loss and loss per diluted share were $20.1 million and $(0.44), respectively, compared with net income and earnings per diluted share of $58.0 million and $1.17, respectively, in the fourth quarter of fiscal 2025.

ADJUSTED RESULTS

Fourth quarter fiscal 2026 organic revenue growth was 4.5% and organic ex-CSL revenue growth was 8.6% compared with the same period of fiscal 2025. Year-over-year organic and organic ex-CSL growth rates by business unit were as follows:

Fourth Quarter Fiscal 2026

OrganicOrganic ex-CSL

Plasma1.8%12.7%

Blood Center5.5%5.5%

Hospital6.5%6.5%

Total net revenue4.5%8.6%

Fourth quarter fiscal 2026 adjusted gross margin was 59.7%, down 50 basis points compared with the prior year period. The primary drivers for the decrease in adjusted gross margin percentage were less favorable mix and impacts from tariffs, partially offset by higher volume and pricing benefits.

Adjusted operating expenses were $122.2 million, up $5.5 million, or 4.7%, when compared with the prior year period. The increase in adjusted operating expenses was largely driven by the acquisition of Vivasure, impacts from tariff and performance-based compensation as well as additional growth investments. A

hae-202602050000313143false00003131432026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter) Massachusetts001-1404104-2882273 (State or other jurisdiction of incorporation) (Commission File Number)(I.R.S. Employer Identification No.)

125 Summer Street Boston, MA 02110 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code 781-848-7100 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, $.01 par value per shareHAENew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition. On February 5, 2026, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d)    Exhibits. Exhibit NumberDescription 99.1 Press Release of Haemonetics Corporation dated February 5, 2026 announcing financial results for the third quarter and nine months ended December 27, 2025.

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

Date: February 5, 2026 By:/s/ Christopher A. Simon Name:Christopher A. Simon Title:President and Chief Executive Officer